Health
Trial testing anti-coronavirus hIVIG plus remdesivir in COVID-19 patients – European Pharmaceutical Review
The ITAC trial will establish if hyperimmune intravenous immunoglobulin (hIVIG) plus remdesivir can improve COVID-19 patient outcomes.
Posted: 9 October 2020 | Hannah Balfour (European Pharmaceutical Review) | No comments yet
The ITAC trial will establish if adding hyperimmune intravenous immunoglobulin (hIVIG) to a remdesivir regimen can improve hospitalised COVID-19 patient outcomes.
A Phase III trial to evaluate the safety, tolerability and efficacy of a combination of the antiviral remdesivir and a highly concentrated solution of SARS-CoV-2 neutralising antibodies in hospitalised adult COVID-19 patients has begun.
The tr…
-
General20 hours agoQueensland government expands youth justice laws, David Crisafulli tells UN critics ‘you don’t control me’
-
General23 hours agoRestaurants on the brink as business failures plateau
-
General19 hours agoCharlotte McConaghy calls for climate change action in new novel Wild Dark Shore
-
General23 hours agoRegional house price growth outstrips capital cities